Other languages MyMD Pharmaceuticals, Inc.

Equities

MYMD

US62856X2018

Market Closed - Nasdaq Other stock markets 01:30:00 01/05/2024 am IST			5-day change	1st Jan Change
3.08 ^USD	+6.21%		+20.31%	-60.31%

18/04	MyMD Pharmaceuticals, Inc. Announces Resignation of Adam Kaplin as Chief Scientific Officer	CI
09/04	Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MyMD Pharmaceuticals, Inc. Announces Resignation of Adam Kaplin as Chief Scientific Officer	19/04
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data	09/04
Investors Eye Wednesday Inflation Data as US Futures Tread Water Tuesday Pre-Bell	09/04
Top Premarket Gainers	09/04
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04
MyMD Pharmaceuticals Regains Compliance With Nasdaq's Minimum Bid Listing Requirement	05/03
MyMD Pharmaceuticals to Implement 1-for-30 Reverse Stock Split	13/02
MyMD Pharmaceuticals, Inc. Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis	06/12
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11
Mymd Pharmaceuticals, Inc. Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD, Reduced Acute Inflammatory Pain	19/23/19
MyMD Pharmaceuticals, Inc. to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-a Market Disrupter, at BioFuture 2023	04/23/04
Insider Buy: Mymd Pharmaceuticals	25/23/25
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15
MyMD Pharmaceuticals Says Its Investigational New Drug Application for Rheumatoid Arthritis Treatment Gets FDA Acceptance	14/23/14
FDA Accepts MyMD Pharmaceuticals, Inc. Investigational New Drug Application for Phase 2 Study of Oral Tnf-A Inhibitor Mymd-1®? in Rheumatoid Arthritis	14/23/14
MyMD Pharmaceuticals' MYMD-1 Study Shows Positive Results for Age-Related inflammation Drug; Shares Rise	31/23/31
Mymd Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral Tnf-A Inhibitor Mymd-1® in Sarcopenia/Age-Related Frailty	31/23/31
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16
MyMD Pharmaceuticals Says Phase 2 Trial of Treatment for Sarcopenia, Frailty Shows No Safety Issues	12/23/12
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	01/23/01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages MyMD Pharmaceuticals, Inc.

Equities

MYMD

US62856X2018

Other languages

Filters